Skip to content
drillr.ai
Sign up

DXCM

DEXCOM INC

NASDAQ · Healthcare · Medical - Devices · US

$88.48
+6.64%
Ask drillr

  • Oct 30, 2026, 16:01 UTC

    DEXCOM INC shares rose after the company reported third-quarter earnings and revenue above estimates and improved its 2026 guidance.

    Source:

  • Oct 29, 2026, 20:03 UTC

    DEXCOM INC reported its third-quarter 2026 financial results.

    Source:

  • Oct 28, 2026, 12:00 UTC

    DexCom announced that its Dexcom G7 15 Day Continuous Glucose Monitoring System will become available in Canada in November 2026 for adults aged 18 and older with diabetes.

    Source:

  • Oct 20, 2026, 15:50 UTC

    DEXCOM INC reported that its G7 continuous glucose monitoring system improved A1C levels and glucose control among non-insulin users with Type 2 diabetes in the DEXCOM INC.

    Source:

  • Oct 6, 2026, 13:00 UTC

    Dexcom launched the fifth season of Dexcom U, its NIL program for college athletes with diabetes, with a record roster of 27 athletes across 13 sports.

    Source:

  • Sep 14, 2026, 20:44 UTC

    DexCom, Inc. promoted Jereme Sylvain to EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.

    Source:

  • Sep 10, 2026, 20:22 UTC

    DexCom Inc. appointed Glenn S. Boehnlein as a director, effective September 10, 2026, with an initial restricted stock unit grant valued at $500,000.

  • Aug 24, 2026, 00:30 UTC

    Dexcom and Health2Sync announced a partnership to integrate continuous glucose monitoring with digital chronic disease management for diabetes care in Australia and Singapore.

    Source:

  • Aug 20, 2026, 07:18 UTC

    Aurora Investment Counsel acquired a new stake in DexCom, Inc., purchasing 34,744 shares valued at approximately $2.34 million in the most recent quarter.

    Source:

  • Jul 30, 2026, 20:08 UTC

    DexCom reported its fiscal Q2 2026 (April-June) financial results, with revenue up 13.1% year-over-year to $1.3084 billion, operating profit up 49.7% to $318.3 million, and diluted EPS of $0.64.

    Source:

  • Jul 27, 2026, 19:59 UTC

    The US Food and Drug Administration selected Dexcom as the first manufacturer for its TEMPO pilot program, allowing digital health devices to be offered to Medicare patients before full authorization.

    Source:

  • Jul 22, 2026, 21:15 UTC

    Dexcom was selected as the first participant in the FDA's TEMPO Digital Health Devices Pilot Program.

    Source:

  • Jul 14, 2026, 15:21 UTC

    DexCom receives Health Canada authorization for its Dexcom G7 15 Day continuous glucose monitoring system.

    Source:

  • Jul 9, 2026, 13:00 UTC

    DexCom, Inc. announced it will release its second quarter 2026 financial results and hold a conference call on July 30, 2026.

    Source:

  • Jul 7, 2026, 11:10 UTC

    Insulet launched its Omnipod 5 automated insulin delivery system in Spain.

    Source:

  • Jun 24, 2026, 14:31 UTC

    DexCom will roll out its redesigned Stelo app in the United States in July, with plans for global expansion and pediatric clearance.

    Source:

  • Jun 16, 2026, 14:56 UTC

    DexCom received FDA clearance for its Stelo OTC continuous glucose monitoring system for children aged 2 and older not using insulin.

    Source:

  • Jun 11, 2026, 10:08 UTC

    Pharmsource LLC stated it was unaware that the Dexcom glucose sensors it purchased from licensed distributors were slated for destruction, after Dexcom warned that some units were stolen during disposal and resold.

    Source: